Help employers find you! Check out all the
TORONTO, July 11, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) Chairman and
Chief Executive Officer, Dr. Tony Cruz is pleased to announce that Carl
Damiani has been appointed to the role of Chief Operating Officer of
"This appointment reflects Mr. Damiani's broader leadership role in
overseeing Transition employees and operations in Toronto, San
Francisco and Ireland, as well as advancing our late stage
neuropsychiatric drug candidate, ELND005, for AD patients, the phase 2
diabetes drug candidate TT-401 partnered with Lilly, and growing our
pipeline with assets acquired from pharma partners", said Dr. Tony
Cruz, Chairman and Chief Executive Officer of Transition.
Since joining Transition in 2003, Mr. Damiani has held the roles of
Vice-President of Business Development and Director of Business
Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. The Company's lead CNS drug
candidate is ELND005 for the treatment of Alzheimer's disease and Down
syndrome. Transition's lead metabolic drug candidate is TT-401
(LY2944876) for the treatment of type 2 diabetes and accompanying
obesity. The Company's shares are listed on the NASDAQ under the symbol
"TTHI" and the Toronto Stock Exchange under the symbol "TTH". For
additional information about the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be
superseded by more recent information we have disclosed in later press
releases, filings with the Canadian Securities Commissions, the U.S.
Securities and Exchange Commission or otherwise. Except for historical
information, this press release may contain forward-looking statements,
relating to expectations, plans or prospects for Transition, including
the total aggregate investment to be made in the Company, the conduct
of clinical trials and the potential efficacy of its products. These
statements are based upon the current expectations and beliefs of
Transition's management and are subject to certain risks and
uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. These risks and
uncertainties include factors beyond Transition's control and the risk
factors and other cautionary statements discussed in Transition's
quarterly and annual filings with the Canadian Securities Commissions
and the U.S. Securities and Exchange Commission.
SOURCE Transition Therapeutics Inc.